Novel opportunities for CFTR-targeting drug development using organoids

Area of Science:

• Biomedical research
• Genetics
• Pharmacology

Background:

• Cystic fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
• Current CF treatments primarily manage symptoms, but targeted therapies addressing the underlying CFTR defect are emerging.
• These novel therapies offer hope for more effective treatments for a wider range of CF patients in the future.

Purpose of the Study:

• To introduce a novel in vitro model for studying cystic fibrosis.
• To explore the utility of this model in discovering new drugs targeting mutant CFTR protein.
• To investigate patient stratification for personalized CFTR-targeted therapies and understand genotype-phenotype variability.

Main Methods:

• Development of a functional assay using patient-derived rectal biopsies.
• Culture of biopsies into self-organizing mini-guts (organoids) for in vitro study.
• Utilizing organoids to test CFTR-targeting drugs and analyze genotype-phenotype correlations.

Main Results:

• The rectal biopsy-derived organoid model successfully recapitulates CFTR function and dysfunction.
• This model is effective in screening potential CFTR-modulating drugs.
• The model aids in understanding how different CFTR mutations influence disease presentation and treatment response.

Conclusions:

• CFTR-targeted pharmacotherapy represents a significant advancement in cystic fibrosis treatment.
• The described organoid model is a valuable tool for accelerating the discovery and development of personalized CF therapies.
• This approach has the potential to improve treatment outcomes for the majority of individuals with CF by addressing specific CFTR mutations.